Second Asia–Pacific Consensus Guidelines for Helicobacter pylori infection
Top Cited Papers
Open Access
- 24 September 2009
- journal article
- review article
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 24 (10), 1587-1600
- https://doi.org/10.1111/j.1440-1746.2009.05982.x
Abstract
The Asia–Pacific Consensus Conference was convened to review and synthesize the most current information on Helicobacter pylori management so as to update the previously published regional guidelines. The group recognized that in addition to long‐established indications, such as peptic ulcer disease, early mucosa‐associated lymphoid tissue (MALT) type lymphoma and family history of gastric cancer, H. pylori eradication was also indicated for H. pylori infected patients with functional dyspepsia, in those receiving long‐term maintenance proton pump inhibitor (PPI) for gastroesophageal reflux disease, and in cases of unexplained iron deficiency anemia or idiopathic thrombocytopenic purpura. In addition, a population ‘test and treat’ strategy for H. pylori infection in communities with high incidence of gastric cancer was considered to be an effective strategy for gastric cancer prevention. It was recommended that H. pylori infection should be tested for and eradicated prior to long‐term aspirin or non‐steroidal anti‐inflammatory drug therapy in patients at high risk for ulcers and ulcer‐related complications. In Asia, the currently recommended first‐line therapy for H. pylori infection is PPI‐based triple therapy with amoxicillin/metronidazole and clarithromycin for 7 days, while bismuth‐based quadruple therapy is an effective alternative. There appears to be an increasing rate of resistance to clarithromycin and metronidazole in parts of Asia, leading to reduced efficacy of PPI‐based triple therapy. There are insufficient data to recommend sequential therapy as an alternative first‐line therapy in Asia. Salvage therapies that can be used include: (i) standard triple therapy that has not been previously used; (ii) bismuth‐based quadruple therapy; (iii) levofloxacin‐based triple therapy; and (iv) rifabutin‐based triple therapy. Both CYP2C19 genetic polymorphisms and cigarette smoking can influence future H. pylori eradication rates.Keywords
This publication has 101 references indexed in Scilit:
- Helicobacter pylori eradication in long‐term proton pump inhibitor users is highly cost‐effective: economic analysis of the HELPUP trialAlimentary Pharmacology & Therapeutics, 2008
- Exploring the cost‐effectiveness ofHelicobacter pyloriscreening to prevent gastric cancer in China in anticipation of clinical trial resultsInternational Journal of Cancer, 2008
- Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trialThe Lancet, 2008
- Changing Antimicrobial Susceptibility Epidemiology of Helicobacter pylori Strains in Japan between 2002 and 2005Journal of Clinical Microbiology, 2007
- American College of Gastroenterology Guideline on the Management of Helicobacter pylori InfectionThe American Journal of Gastroenterology, 2007
- Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus ReportGut, 2007
- Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER StudyGut, 2007
- Prevention of gastric cancer: urgent need to implement Helicobacter pylori eradication therapy as a primary preventive measure in JapanThe Esophagus, 2007
- Development of reflux esophagitis following Helicobacter pylori eradicationThe Esophagus, 2005
- Second-line treatment for Helicobacter pylori infection in Japan: proton pump inhibitor-based amoxicillin and metronidazole regimenThe Esophagus, 2004